
Journal of International Obstetrics and Gynecology ›› 2022, Vol. 49 ›› Issue (4): 376-381.doi: 10.12280/gjfckx.20211187
• Research on Gynecological Malignancies: Review • Previous Articles Next Articles
ZHANG Ding-ding, LIANG Jing-qing, GU Nan-nan, LIU Su-fen(
)
Received:2021-12-29
Published:2022-08-15
Online:2022-08-19
Contact:
LIU Su-fen
E-mail:liusufen11978@126.com
ZHANG Ding-ding, LIANG Jing-qing, GU Nan-nan, LIU Su-fen. The Mechanism of LncRNA in the Proliferation and Invasion of Ovarian Cancer[J]. Journal of International Obstetrics and Gynecology, 2022, 49(4): 376-381.
Add to citation manager EndNote|Ris|BibTeX
| [1] |
李艺, 祝洪澜, 昌晓红, 等. 初诊晚期上皮性卵巢癌的规范化治疗[J]. 现代妇产科进展, 2020, 29(10):778-787. doi: 10.13283/j.cnki.xdfckjz.2020.10.011.
doi: 10.13283/j.cnki.xdfckjz.2020.10.011 |
| [2] |
余敏华, 金明珠, 狄文. PARP抑制剂卵巢癌治疗研究进展[J]. 现代妇产科进展, 2021, 30(6):470-474. doi: 10.13283/j.cnki.xdfckjz.2021.06.017.
doi: 10.13283/j.cnki.xdfckjz.2021.06.017 |
| [3] |
Xu H, Wang L, Jiang X. Silencing of lncRNA DLEU1 inhibits tumorigenesis of ovarian cancer via regulating miR-429/TFAP2A axis[J]. Mol Cell Biochem, 2021, 476(2):1051-1061. doi: 10.1007/s11010-020-03971-9.
doi: 10.1007/s11010-020-03971-9 |
| [4] |
Tong L, Wang Y, Ao Y, et al. CREB1 induced lncRNA HAS2-AS1 promotes epithelial ovarian cancer proliferation and invasion via the miR-466/RUNX2 axis[J]. Biomed Pharmacother, 2019, 115:108891. doi: 10.1016/j.biopha.2019.108891.
doi: 10.1016/j.biopha.2019.108891 |
| [5] |
Liu B, Luo C, Lin H, et al. Long Noncoding RNA XIST Acts as a ceRNA of miR-362-5p to Suppress Breast Cancer Progression[J]. Cancer Biother Radiopharm, 2021, 36(6):456-466. doi: 10.1089/cbr.2019.3481.
doi: 10.1089/cbr.2019.3481 |
| [6] | Wei GH, Wang X. lncRNA MEG3 inhibit proliferation and metastasis of gastric cancer via p53 signaling pathway[J]. Eur Rev Med Pharmacol Sci, 2017, 21(17):3850-3856. |
| [7] |
Hua Q, Mi B, Xu F, et al. Hypoxia-induced lncRNA-AC020978 promotes proliferation and glycolytic metabolism of non-small cell lung cancer by regulating PKM2/HIF-1α axis[J]. Theranostics, 2020, 10(11):4762-4778. doi: 10.7150/thno.43839.
doi: 10.7150/thno.43839 |
| [8] |
Li T, Liu N, Gao Y, et al. Long noncoding RNA HOTAIR regulates the invasion and metastasis of prostate cancer by targeting hepaCAM[J]. Br J Cancer, 2021, 124(1):247-258. doi: 10.1038/s41416-020-01091-1.
doi: 10.1038/s41416-020-01091-1 |
| [9] |
He X, Yu B, Kuang G, et al. Long noncoding RNA DLEU2 affects the proliferative and invasive ability of colorectal cancer cells[J]. J Cancer, 2021, 12(2):428-437. doi: 10.7150/jca.48423.
doi: 10.7150/jca.48423 |
| [10] |
Li T, Chen Y, Zhang J, et al. LncRNA TUG1 promotes cells proliferation and inhibits cells apoptosis through regulating AURKA in epithelial ovarian cancer cells[J]. Medicine(Baltimore), 2018, 97(36):e12131. doi: 10.1097/MD.0000000000012131.
doi: 10.1097/MD.0000000000012131 |
| [11] |
Liu S, Liu Y, Lu Q, et al. The lncRNA TUG1 promotes epithelial ovarian cancer cell proliferation and invasion via the WNT/β-catenin pathway[J]. Onco Targets Ther, 2018, 11:6845-6851. doi: 10.2147/OTT.S167900.
doi: 10.2147/OTT.S167900 |
| [12] |
Zhan FL, Chen CF, Yao MZ. LncRNA TUG1 facilitates proliferation, invasion and stemness of ovarian cancer cell via miR-186-5p/ZEB1 axis[J]. Cell Biochem Funct, 2020, 38(8):1069-1078. doi: 10.1002/cbf.3544.
doi: 10.1002/cbf.3544 |
| [13] |
Yu M, Zhan J, Zhang HQ. HOX family transcription factors: Related signaling pathways and post-translational modifications in cancer[J]. Cell Signal, 2020, 66:109469. doi: 1016/j.cellsig.2019.109469.
doi: 1016/j.cellsig.2019.109469 |
| [14] |
Xu S, Jia G, Zhang H, et al. LncRNA HOXB-AS3 promotes growth, invasion and migration of epithelial ovarian cancer by altering glycolysis[J]. Life Sci, 2021, 264:118636. doi: 10.1016/j.lfs.2020.118636.
doi: 10.1016/j.lfs.2020.118636 |
| [15] |
Zhang Y, Dun Y, Zhou S, et al. LncRNA HOXD-AS1 promotes epithelial ovarian cancer cells proliferation and invasion by targeting miR-133a-3p and activating Wnt/β-catenin signaling pathway[J]. Biomed Pharmacother, 2017, 96:1216-1221. doi: 10.1016/j.biopha.2017.11.096.
doi: S0753-3322(17)34468-2 pmid: 29239819 |
| [16] |
Goyal B, Yadav SRM, Awasthee N, et al. Diagnostic, prognostic, and therapeutic significance of long non-coding RNA MALAT1 in cancer[J]. Biochim Biophys Acta Rev Cancer, 2021, 1875(2): 188502. doi: 10.1016/j.bbcan.2021.188502.
doi: 10.1016/j.bbcan.2021.188502 |
| [17] |
Liao H, Chen Q, Xiao J. Reflections on the role of MALAT1 in gynecological cancer[J]. Cancer Manag Res, 2020, 12:13489-13500. doi: 10.2147/CMAR.S286804.
doi: 10.2147/CMAR.S286804 |
| [18] |
Sun Q, Li Q, Xie F. LncRNA-MALAT1 regulates proliferation and apoptosis of ovarian cancer cells by targeting miR-503-5p[J]. Onco Targets Ther, 2019, 12:6297-6307. doi: 10.2147/OTT.S214689.
doi: 10.2147/OTT.S214689 |
| [19] | Jin Y, Feng SJ, Qiu S, et al. LncRNA MALAT1 promotes proliferation and metastasis in epithelial ovarian cancer via the PI3K-AKT pathway[J]. Eur Rev Med Pharmacol Sci, 2017, 21(14):3176-3184. |
| [20] |
Li S, Li J, Chen C, et al. Pan-cancer analysis of long non-coding RNA NEAT1 in various cancers[J]. Genes Dis, 2017, 5(1):27-35. doi: 10.1016/j.gendis.2017.11.003.
doi: 10.1016/j.gendis.2017.11.003 |
| [21] |
Yuan J, Yi K, Yang L. LncRNA NEAT1 promotes proliferation of ovarian cancer cells and angiogenesis of co-incubated human umbilical vein endothelial cells by regulating FGF9 through sponging miR-365: An experimental study[J]. Medicine(Baltimore), 2021, 100(3):e23423. doi: 10.1097/MD.0000000000023423.
doi: 10.1097/MD.0000000000023423 |
| [22] |
Yin L, Wang Y. Long non-coding RNA NEAT1 facilitates the growth,migration,and invasion of ovarian cancer cells via the let-7g/MEST/ATGL axis[J]. Cancer Cell Int, 2021, 21(1):437. doi: 10.1186/s12935-021-02018-3.
doi: 10.1186/s12935-021-02018-3 |
| [23] |
Pang B, Sui S, Wang Q, et al. Upregulation of DLEU1 expression by epigenetic modification promotes tumorigenesis in human cancer[J]. J Cell Physiol, 2019, 234(10):17420-17432. doi: 10.1002/jcp.28364.
doi: 10.1002/jcp.28364 |
| [24] |
Xu C, Zhu LX, Sun DM, et al. Regulatory mechanism of lncRNA NORAD on proliferation and invasion of ovarian cancer cells through miR-199a-3p[J]. Eur Rev Med Pharmacol Sci, 2020, 24(4):1672-1681. doi: 10.26355/eurrev_202002_20341.
doi: 10.26355/eurrev_202002_20341 |
| [25] |
Tong LL, Ao Y, Zhang HJ, et al. Long noncoding RNA NORAD is upregulated in epithelial ovarian cancer and its downregulation suppressed cancer cell functions by competing with miR-155-5p[J]. Cancer Med, 2019, 8(10):4782-4791. doi: 10.1002/cam4.2350.
doi: 10.1002/cam4.2350 |
| [26] |
Mu Y, Li N, Cui YL. The lncRNA CCAT1 upregulates TGFβR1 via sponging miR-490-3p to promote TGFβ1-induced EMT of ovarian cancer cells[J]. Cancer Cell Int, 2018, 18:145. doi: 10.1186/s12935-018-0604-1.
doi: 10.1186/s12935-018-0604-1 |
| [27] |
Lai XJ, Cheng HF. LncRNA colon cancer-associated transcript 1 (CCAT1) promotes proliferation and metastasis of ovarian cancer via miR-1290[J]. Eur Rev Med Pharmacol Sci, 2018, 22(2):322-328. doi: 10.26355/eurrev_201801_14175.
doi: 10.26355/eurrev_201801_14175 |
| [28] |
Sun NX, Ye C, Zhao Q, et al. Long noncoding RNA-EBIC promotes tumor cell invasion by binding to EZH2 and repressing e-cadherin in cervical cancer[J]. PLoS One, 2014, 9(7):e100340. doi: 10.1371/journal.pone.0100340.
doi: 10.1371/journal.pone.0100340 |
| [29] |
Xu QF, Tang YX, Wang X. LncRNA EBIC promoted proliferation, metastasis and cisplatin resistance of ovarian cancer cells and predicted poor survival in ovarian cancer patients[J]. Eur Rev Med Pharmacol Sci, 2018, 22(14):4440-4447. doi: 10.26355/eurrev_ 201807_15495.
doi: 10.26355/eurrev_ 201807_15495 |
| [30] | Tao P, Yang B, Zhang H, et al. The overexpression of lncRNA MEG3 inhibits cell viability and invasion and promotes apoptosis in ovarian cancer by sponging miR-205-5p[J]. Int J Clin Exp Pathol, 2020, 13(5):869-879. |
| [31] |
Wang J, Xu W, He Y, et al. LncRNA MEG3 impacts proliferation, invasion, and migration of ovarian cancer cells through regulating PTEN[J]. Inflamm Res, 2018, 67(11/12):927-936. doi: 10.1007/s00011-018-1186-z.
doi: 10.1007/s00011-018-1186-z |
| [32] |
Jiang R, Zhang H, Zhou J, et al. Inhibition of long non-coding RNA XIST upregulates microRNA-149-3p to repress ovarian cancer cell progression[J]. Cell Death Dis, 2021, 12(2):145. doi: 10.1038/s41419-020-03358-0.
doi: 10.1038/s41419-020-03358-0 pmid: 33542185 |
| [33] |
Wang CH, Qi S, Xie C, et al. Upregulation of long non-coding RNA XIST has anticancer effects on epithelial ovarian cancer cells through inverse downregulation of has-miR-214-3p[J]. J Gynecol Oncol, 2018, 29(6):e99. doi: 10.3802/jgo.2018.29.e99.
doi: 10.3802/jgo.2018.29.e99 |
| [34] |
Guo T, Yuan D, Zhang W, et al. Upregulation of long noncoding RNA XIST has anticancer effects on ovarian cancer through sponging miR-106a[J]. Hum Cell, 2021, 34(2):579-587. doi: 10.1007/s13577-020-00469-w.
doi: 10.1007/s13577-020-00469-w |
| [35] |
Cui K, Zhu G. LncRNA CTBP1-AS2 regulates miR-216a/ PTEN to suppress ovarian cancer cell proliferation[J]. J Ovarian Res, 2020, 13(1):84. doi: 10.1186/s13048-020-00689-6.
doi: 10.1186/s13048-020-00689-6 |
| [1] | WU Hua-tuo, HUANG Chun-lin, MA Yan, GE Ting, LI Li. Research Progress on the Immune Microenvironment of Ovarian Cancer [J]. Journal of International Obstetrics and Gynecology, 2026, 53(3): 297-301. |
| [2] | XU Meng-ting, LU Di, SONG Dian-rong. Research Progress in the Tumor Microenvironment of Ovarian Cancer [J]. Journal of International Obstetrics and Gynecology, 2026, 53(2): 188-193. |
| [3] | WANG Ju-peng, REN Li, MA Ming-kun, ZHAO Ran, WEN Xue-hong. Expression Characteristics of KRT18 in Ovarian Cancer and Its Association with Patient Survival and Tumor Immune Microenvironment [J]. Journal of International Obstetrics and Gynecology, 2026, 53(2): 211-219. |
| [4] | ZHANG Meng-jie, JIAO Jin-wen, WANG Li-ming. A Case of Port Site Metastasis Secondary to Abdominal Paracentesis Drainage in Advanced Ovarian Cancer [J]. Journal of International Obstetrics and Gynecology, 2026, 53(2): 237-240. |
| [5] | XU Tian, PING Yi. Research Progress on Non-Coding RNAs Regulation of Ferroptosis in Ovarian Cancer [J]. Journal of International Obstetrics and Gynecology, 2026, 53(1): 12-17. |
| [6] | LI Na, LIU Hai-yan, TAN Li-li. Primary Ovarian Epithelioid Angiosarcoma:A Case Report [J]. Journal of International Obstetrics and Gynecology, 2026, 53(1): 22-26. |
| [7] | LI Xue-jian, WU Bo-qiong, WEN Jin-ying, PENG Jian-feng, CHEN Yu. Low-Grade Appendiceal Mucinous Neoplasm Misdiagnosed as Ovarian Tumor: A Case Report [J]. Journal of International Obstetrics and Gynecology, 2026, 53(1): 33-37. |
| [8] | XU Ruo-lan, YANG Jiang, WANG Ran-ran, ZHOU Jin-ting. Research Progress on Circulating Tumor DNA in the Early Diagnosis of Ovarian Cancer [J]. Journal of International Obstetrics and Gynecology, 2026, 53(1): 8-11. |
| [9] | GAO Yue, SHI Bai-chao, YU Jian-nan, ZHANG Li-qian, WANG Yu, WU Xiao-ke. Research Progress on the Anti-Gynecological Malignancy Effects of Chinese Herbal Polysaccharides [J]. Journal of International Obstetrics and Gynecology, 2025, 52(6): 685-689. |
| [10] | XIE Jiu-mei, WANG Yu, CHEN Xiang-nan, ZHANG Li-qian, WU Xiao-ke. Research Progress on the Intervention of Ovarian Cancer by Chinese Medicine Monomers and Compounds through Regulating the NF-κB Signaling Pathway [J]. Journal of International Obstetrics and Gynecology, 2025, 52(6): 690-695. |
| [11] | SUN Ya-ge, ZHANG Yun-feng, LU Yue, GUO Jing-jing, XIANG Xiao-ying, JIA Han, WANG Yue. Research Progress on the cGAS-STING Signaling Pathway in Ovarian Cancer [J]. Journal of International Obstetrics and Gynecology, 2025, 52(6): 696-701. |
| [12] | ZHOU Yuan, WANG Zhen-zhen, CAO Meng-dong, YU Han, SHEN Xue. Misdiagnosis of Pelvic Splenosis as Ovarian Tumor: A Case Report [J]. Journal of International Obstetrics and Gynecology, 2025, 52(6): 708-711. |
| [13] | ZHOU Ling-ling, SONG Jian-dong, Sarina . Research Progress of LncRNA HOTAIR in Gynecological Malignant Tumors [J]. Journal of International Obstetrics and Gynecology, 2025, 52(5): 481-485. |
| [14] | QIN Chen, ZHANG Wei, LI Li. Role of Lipid Metabolism Reprogramming in the Progression and Drug Resistance of Ovarian Cancer [J]. Journal of International Obstetrics and Gynecology, 2025, 52(5): 492-497. |
| [15] | ZHANG Li-qian, WANG Yu, GAO Yue, BAI Yu-xin, FAN Rui-rui, XIE Jiu-mei, WU Xiao-ke. Research Progress on the Mechanism of Quercetin against Cervical Cancer [J]. Journal of International Obstetrics and Gynecology, 2025, 52(4): 425-430. |
| Viewed | ||||||
|
Full text |
|
|||||
|
Abstract |
|
|||||